Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
J Ferdinandus, E Eppard, FC Gaertner… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostate-specific membrane
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
[PDF][PDF] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
J Ferdinandus, E Eppard, FC Gaertner… - THE JOURNAL OF …, 2017 - scholar.archive.org
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostatespecific membrane
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
J Ferdinandus, E Eppard, FC Gaertner… - Journal of Nuclear …, 2016 - europepmc.org
Methods RLT was performed in 40 hormone-refractory patients with distant metastases and
progressive disease (mean age, 71.4 y). 68 Ga-PSMA-11 PET/CT was performed in all …
progressive disease (mean age, 71.4 y). 68 Ga-PSMA-11 PET/CT was performed in all …
[引用][C] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
J Ferdinandus, E Eppard, FC Gaertner… - Journal of Nuclear …, 2016 - cir.nii.ac.jp
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate
Cancer with 177Lu-PSMA-617 | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ …
Cancer with 177Lu-PSMA-617 | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ …
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
J Ferdinandus, E Eppard… - Journal of nuclear …, 2017 - pubmed.ncbi.nlm.nih.gov
Radioligand therapy (RLT) with 177 Lu-PSMA-617 (PSMA is prostate-specific membrane
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
[PDF][PDF] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
J Ferdinandus, E Eppard, FC Gaertner… - THE JOURNAL OF …, 2017 - Soc Nuclear Med
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostatespecific membrane
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …